Superhydrophobic drug-loaded mesoporous silica nanoparticles capped with β-cyclodextrin for ultrasound image-guided combined antivascular and chemo-sonodynamic therapy

Ho, Yi-Ju; Wu, Chi Hao; Jin, Qiaofeng; Lin, Chih Yu; Chiang, Pei Hua; Wu, Nan; Fan, Chih‐Peng; Yang, Chia Min; Yeh, Chih Kuang

doi:10.1016/j.biomaterials.2019.119723

Cited by 74 publications

(50 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This nanoplatform could not only destroy tumor blood vessels but also achieve targeted chemotherapy, thus obtaining excellent therapeutic effects in solid tumor models. Similarly, the DOX‐loaded interfacial nanobubble system also showed US‐enhanced chemotherapy effects (Ho et al, 2020). In addition, the ability of iron oxide nanoparticle to destroy microtubule structures during hyperthermia therapy has also attracted the attention of researchers (X. Wu et al, 2010).…”

Section: Engineered Nanomedicines For Vascular Disruption Strategymentioning

confidence: 98%

“…The use of US or a magnetic field to cause energy conversion of nanoparticles, thus resulting in vascular damage, has also been extensively studied. Metal nanoparticles are the most widely used nanoparticles to cause physical damage to tumor blood vessel walls (Detappe et al, 2013; Diagaradjane et al, 2008; Ho et al, 2020; Ho & Yeh, 2017; Ngwa, Makrigiorgos, & Berbeco, 2010, 2012; X. Wu, Tan, Mao, & Zhang, 2010). Au NP could distribute effectively around tumor blood vessels (Diagaradjane et al, 2008), mediating the effects of IR light‐induced photothermal and radiation therapy focused on the tumor blood vessels.…”

Section: Engineered Nanomedicines For Vascular Disruption Strategymentioning

confidence: 99%

See 1 more Smart Citation

Engineered nanomedicines for tumor vasculature blockade therapy

Zhao

Huang

Zhang

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Tumor vasculature blockade therapy (TVBT), including angiogenesis inhibition, vascular disruption, and vascular infarction, provides a promising treatment modality for solid tumors. However, low selectivity, drug resistance, and possible severe side effects have limited the clinical transformation of TVBT. Engineered nanoparticles offer potential solutions, including prolonged circulation time, targeted transportation, and controlled release of TVBT agents. Moreover, engineered nanomedicines provide a promising combination platform of TVBT with chemotherapy, radiotherapy, photodynamic therapy, photothermal therapy, ultrasound therapy, and gene therapy. In this article, we offer a comprehensive summary of the current progress of engineered nanomedicines for TVBT and also discuss current deficiencies and future directions for TVBT development. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Section: Engineered Nanomedicines For Vascular Disruption Strategymentioning

confidence: 98%

Section: Engineered Nanomedicines For Vascular Disruption Strategymentioning

confidence: 99%

Engineered nanomedicines for tumor vasculature blockade therapy

Zhao

Huang

Zhang

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…-cyclodextrin ( CD) is a nontoxic oligosaccharide, the special hydrophilic shell and hydrophobic cavity allow it to serve as modifier to improve the wettability and biocompatibility. CD has been widely used in the field of medicine and food, [17][18][19][20] such as slow-release drug capsules by using the host-guest interaction, the hydrophobic inner core of the CD fits with most of the organic drug molecular size. Introducing CD to PCL endows the hybrid material with ideal action site for drug inclusion to perform drug loading and controlled release.…”

Section: Introductionmentioning

confidence: 99%

4D Printing of Shape Memory Vascular Stent Based on βCD‐g‐Polycaprolactone

Zhou

Cao

et al. 2021

Macromol. Rapid Commun.

View full text Add to dashboard Cite

The 4D-printing technology is applied to fabricate a shape memory peripheral stent with good biocompatibility, which sustains long-term drug release. The star polymer s-PCL is prepared by ring opening polymerization of -caprolactone with the -OH of -cyclodextrin ( CD) as initiator, and then the s-PCL is modified with acrylate endgroup which allows the polymerization under UV light to form the crosslinking network c-PCL. Attributed to the feature of the high crosslinked structure and chemical nature of polycaprolactone (PCL) and CD, the composite exhibits appropriate tensile strength and sufficient elasticity and bursting pressure, and it is comparable with great saphenous vein in human body. The radial support of the 4D-printed stent is 0.56 ± 0.11 N and is equivalent to that of commercial stent. The cell adhesion and proliferation results show a good biocompatibility of the stent with human umbilical vein endothelial cells. Due to the presence of CD, the wettability and biocompatibility of the materials are improved, and the sustained paclitaxel release based on the host-guest complexion shows the potential of the drug-loaded stent for long-term release. This study provides a new strategy to solve the urgent need of small-diameter scaffolds to treat critical limb ischemia.

show abstract

“…Current treatment is based on different combinations of chemotherapy and exterior beam radiation, which have been unsuccessful in improving survival, where average survival rates are 4-6 months with less than 20% survival in 12 months (Tokranova et al, 2013;Liu et al, 2018;Yang et al, 2020). Therefore, new theranostic approaches for initial detection and efficient ATC treatment are needed (Iwashina et al, 2006;Kang et al, 2019;Ho et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Precise engineering of cetuximab encapsulated gadollium nanoassemblies: in vitro ultrasound diagnosis and in vivo thyroid cancer therapy

Qi¹,

Gao²,

Nie³

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

We report the formulation of nanoassemblies (NAs) comprising C225 conjugates Gd-PFH-NAs (C-Gd-PFH-NAs) for low-intensity focused ultrasound diagnosis ablation of thyroid cancer. C-Gd-PFH-NAs showed excellent stability in water, phosphate-buffered saline (PBS), and 20% rat serum. Transmission electron microscopy (TEM) images also revealed the effective construction of C-Gd-PFH-NAs as common spherical assemblies. The incubation of C625 thyroid carcinoma with C-Gd-PFH-NAs triggers apoptosis, as confirmed by flow cytometry analysis. The C-Gd-PFH-NAs exhibited antitumor efficacy in human thyroid carcinoma xenografts, where histopathological results further confirmed these outcomes. Furthermore, we were able to use low-intensity focused ultrasound diagnosis imaging (LIFUS) to examine the efficiency of C-Gd-PFH-NAs in thyroid carcinoma in vivo. These findings clearly show that the use of LIFUS agents with high performance imaging in different therapeutic settings will have extensive potential for future biomedical applications.

show abstract

Superhydrophobic drug-loaded mesoporous silica nanoparticles capped with β-cyclodextrin for ultrasound image-guided combined antivascular and chemo-sonodynamic therapy

Cited by 74 publications

References 36 publications

Engineered nanomedicines for tumor vasculature blockade therapy

Engineered nanomedicines for tumor vasculature blockade therapy

4D Printing of Shape Memory Vascular Stent Based on βCD‐g‐Polycaprolactone

Precise engineering of cetuximab encapsulated gadollium nanoassemblies: in vitro ultrasound diagnosis and in vivo thyroid cancer therapy

Contact Info

Product

Resources

About